PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.49%
Revenue growth at 50-75% of CVE's 28.26%. Martin Whitman would worry about competitiveness or product relevance.
31.21%
Gross profit growth above 1.5x CVE's 2.73%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
134.02%
EBIT growth above 1.5x CVE's 85.00%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
134.02%
Operating income growth above 1.5x CVE's 85.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
285.71%
Positive net income growth while CVE is negative. John Neff might see a big relative performance advantage.
282.76%
Positive EPS growth while CVE is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
282.76%
Positive diluted EPS growth while CVE is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
0.18%
Diluted share reduction more than 1.5x CVE's 0.65%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-31.12%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-291.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
176.77%
10Y revenue/share CAGR above 1.5x CVE's 32.24%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-52.12%
Negative 5Y CAGR while CVE stands at 32.24%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-72.94%
Negative 3Y CAGR while CVE stands at 32.24%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
537.27%
Positive long-term OCF/share growth while CVE is negative. John Neff would see a structural advantage in sustained cash generation.
-63.04%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-62.37%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
4.07%
Positive 10Y CAGR while CVE is negative. John Neff might see a substantial advantage in bottom-line trajectory.
-92.90%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-12.35%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
627.17%
Equity/share CAGR of 627.17% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
36.80%
Equity/share CAGR of 36.80% while CVE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-10.95%
Negative 3Y equity/share growth while CVE is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
917.44%
Dividend/share CAGR of 917.44% while CVE is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
208.07%
Dividend/share CAGR of 208.07% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
-48.79%
Negative near-term dividend growth while CVE invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
11.12%
AR growth well above CVE's 5.66%. Michael Burry fears inflated revenue or higher default risk in the near future.
-33.33%
Inventory is declining while CVE stands at 6.82%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.70%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-2.38%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
5.11%
Debt growth far above CVE's 0.64%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
38.78%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.